Eric Chatelain

5.5k citations

63 papers · 3.6k indexed · 1 hit paper · h-index 31

Impact in

Public Health, Environmental and Occupational Health top 0.5%
- Research on Leishmaniasis Studies
Epidemiology top 1%
- Trypanosoma species research and implications

Papers in ⓘ

Public Health, Environmental and Occupational Health 45
- Research on Leishmaniasis Studies 44
Epidemiology 47
- Trypanosoma species research and implications 46

Co-authors: B. Gabard (3 shared papers)Lúcio H. Freitas-Júnior (8 shared papers)C Wirbelauer (1 shared paper)Hedwig Sutterlüty (1 shared paper)Uli Müller (1 shared paper)Jean‐Robert Ioset (9 shared papers)Jair L. Siqueira-Neto (3 shared papers)Helena Andrade (1 shared paper)
Journals: PLoS neglected tropical diseases (5 papers)Journal of Medicinal Chemistry (4 papers)Antimicrobial Agents and Chemotherapy (4 papers)Bioorganic & Medicinal Chemistry (4 papers)International Journal for Parasitology Drugs and Drug Resistance (3 papers)
Partner nations: Switzerland United States United Kingdom

In The Last Decade

Eric Chatelain

62 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells 1999 · 610 citations

Peers

Countries citing papers authored by Eric Chatelain

Since Specialization

Citations

This map shows the geographic impact of Eric Chatelain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Chatelain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Chatelain more than expected).

Fields of papers citing papers by Eric Chatelain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Chatelain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Chatelain. The network helps show where Eric Chatelain may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric Chatelain, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Chatelain Line = papers co-authored together Eric Chatelain links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 63 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells Nature Cell Biology ·Hedwig Sutterlüty, Eric Chatelain, Alain Marti, C Wirbelauer, Matthias Senften, Uli Müller, Wilhelm Krek Hit paper breakdown →	1999	610
2	Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? International Journal for Parasitology Drugs and Drug Resistance ·Lúcio H. Freitas-Júnior, Eric Chatelain, Helena Andrade, Jair L. Siqueira-Neto	2012	213
3	Chagas Disease Drug Discovery: Toward a New Era SLAS DISCOVERY ·Eric Chatelain	2014	212
4	Photostabilization of Butyl methoxydibenzoylmethane (Avobenzone) and Ethylhexyl methoxycinnamate by Bis-ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S), a New UV Broadband Filter¶ Photochemistry and Photobiology ·Eric Chatelain, B. Gabard	2001	168
5	Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development Scientific Reports ·Carolina Borsoi Moraes, Miriam A. Giardini, Hwayoung Kim, Caio Haddad Franco, Adalberto M. Araujo-Junior, Sérgio Schenkman, Eric Chatelain, Lúcio H. Freitas-Júnior	2014	151
6	Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienols Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Eric Chatelain, Daniel Boscoboinik, Gianna-M. Bartoli, Valerian E. Kagan, Fred Gey, Lester Packer, Angelo Azzi	1993	138
7	Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds PLoS neglected tropical diseases ·Jair L. Siqueira-Neto, Ok‐Ryul Song, Hyun Lim Oh, Jeong‐Hun Sohn, Gyongseon Yang, Jiyoun Nam, Jiyeon Jang, Jonathan Cechetto, Chang Bok Lee, Seung‐Hyun Moon, Auguste Genovesio, Eric Chatelain, Thierry Christophe, Lúcio H. Freitas-Júnior	2010	127
8	Skin Penetration and Sun Protection Factor of Five UV Filters: Effect of the Vehicle Skin Pharmacology and Physiology ·Eric Chatelain, B. Gabard, Christian Surber	2003	123
9	Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging Antimicrobial Agents and Chemotherapy ·Amanda Fortes Francisco, Michael D. Lewis, Shiromani Jayawardhana, Martin C. Taylor, Eric Chatelain, John M. Kelly	2015	115
10	Chagas disease research and development: Is there light at the end of the tunnel? Computational and Structural Biotechnology Journal ·Eric Chatelain	2016	107
11	An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages PLoS neglected tropical diseases ·Jair L. Siqueira-Neto, Seung‐Hyun Moon, Jiyeon Jang, Gyongseon Yang, Changbok Lee, Hong Kee Moon, Eric Chatelain, Auguste Genovesio, Jonathan Cechetto, Lúcio H. Freitas-Júnior	2012	105
12	Translational challenges of animal models in Chagas disease drug development: a review Drug Design Development and Therapy ·Eric Chatelain, Nandini Konar	2015	96
13	Novel 3-Nitro-1H-1,2,4-triazole-Based Amides and Sulfonamides as Potential Antitrypanosomal Agents Journal of Medicinal Chemistry ·Maria V. Papadopoulou, William D. Bloomer, Howard S. Rosenzweig, Eric Chatelain, Marcel Kaiser, Shane R. Wilkinson, Caroline McKenzie, Jean‐Robert Ioset	2012	90
14	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern Nature Communications ·Rana Abdelnabi, Caroline S. Foo, Dirk Jochmans, Laura Vangeel, Steven De Jonghe, Patrick Augustijns, Raf Mols, Birgit Weynand, Thanaporn Wattanakul, Richard M. Hoglund, Joel Tärning, Charles E. Mowbray, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain, Johan Neyts	2022	84
15	Phenotypic screening approaches for Chagas disease drug discovery Expert Opinion on Drug Discovery ·Eric Chatelain, Jean‐Robert Ioset	2017	72
16	Identification of Compounds with Anti-Proliferative Activity against Trypanosoma brucei brucei Strain 427 by a Whole Cell Viability Based HTS Campaign PLoS neglected tropical diseases ·Melissa L. Sykes, Jonathan B. Baell, Marcel Kaiser, Eric Chatelain, Sarah R. Moawad, Danny Ganame, Jean‐Robert Ioset, Vicky M. Avery	2012	70
17	Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage Scientific Reports ·Amanda Fortes Francisco, Shiromani Jayawardhana, Michael D. Lewis, Karen L. White, David M. Shackleford, Gong Chen, Jessica Saunders, Maria Osuna‐Cabello, Kevin D. Read, Susan A. Charman, Eric Chatelain, John M. Kelly	2016	69
18	Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease Journal of Biological Chemistry ·Tatiana Y. Hargrove, Z. Wawrzak, Paul W. Alexander, Jason H. Chaplin, Martine Keenan, Susan A. Charman, Catherine Perez, Michael R. Waterman, Eric Chatelain, Galina I. Lepesheva	2013	67
19	Antitrypanosomal Activity of Fexinidazole Metabolites, Potential New Drug Candidates for Chagas Disease Antimicrobial Agents and Chemotherapy ·Maria Terezinha Bahia, Alvaro F. S. Nascimento, Ana Lia Mazzeti, Luiz Felipe Baldo Marques, Karolina Ribeiro Gonçalves, Ludmilla Walter Reis Mota, Lívia de Figueiredo Diniz, Ivo Santana Caldas, André Talvani, David M. Shackleford, Maria Koltun, Jessica Saunders, Karen L. White, Ivan Scandale, Susan A. Charman, Eric Chatelain	2014	55
20	d-α-tocopherol control of cell proliferation Molecular Aspects of Medicine ·Angelo Azzi, Daniel Boscoboinik, Eric Chatelain, Nesrin Kartal Özer, Barbara Stäuble	1993	51

About Eric Chatelain

Eric Chatelain is a scholar working on Public Health, Environmental and Occupational Health, Epidemiology, Organic Chemistry, Biochemistry and Parasitology, having authored 63 papers that have together received 3.6k indexed citations. Recurring topics across this work include Trypanosoma species research and implications (46 papers), Research on Leishmaniasis Studies (44 papers), Synthesis and Biological Evaluation (26 papers), Biochemical and Molecular Research (4 papers), SARS-CoV-2 and COVID-19 Research (4 papers), Antioxidant Activity and Oxidative Stress (4 papers), Free Radicals and Antioxidants (3 papers) and Insect symbiosis and bacterial influences (3 papers). The work is most often cited by research in Public Health, Environmental and Occupational Health (1.6k citations), Epidemiology (1.7k citations), Organic Chemistry (1.2k citations), Parasitology (220 citations) and Biochemistry (192 citations). Eric Chatelain has collaborated with scholars based in Switzerland, United States and United Kingdom. Frequent co-authors include B. Gabard, Lúcio H. Freitas-Júnior, C Wirbelauer, Hedwig Sutterlüty, Uli Müller, Jean‐Robert Ioset, Jair L. Siqueira-Neto, Helena Andrade, Christian Surber and Angelo Azzi. Their work appears in journals such as PLoS neglected tropical diseases, Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy, Bioorganic & Medicinal Chemistry and International Journal for Parasitology Drugs and Drug Resistance.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact